




Patent Docket P1365R2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Daniel J. Burdick et al. Serial No.: 10/649,762 Filed: August 26, 2003 For: ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS	Group Art Unit: NOT KNOWN Examiner: NOT KNOWN Confirmation No: 7341 CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on February 6, 2004  Aida Guiam
--	---

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of



THIS PAGE BLANK (USPTO)

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

Those patents or publications which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior applications Serial No. 09/646,330, filed September 14, 2000 and Serial No. 09/275,480, filed March 24, 1999 and relied upon in this application for an earlier filing date under 35 USC §120. Applicants also enclose copies of forms PTO-1449 and PTO-892 from the above-mentioned previous applications.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of

THIS PAGE BLANK (USPTO)

computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1 - A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) [Required]
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,
GENENTECH, INC.

Date: February 6, 2004

By: 
David W Evans
Reg. No. *
Telephone No. (650) 225-1739

1 DNA Way
South San Francisco, CA 94080-4990
Fax: (650) 952-9881

* A copy of a document pursuant to 37 C.F.R. § 10.9(b) is attached as proof of the authorization of the above to prosecute the attached application. The original of this document is on file in the Office of enrollment and Discipline.

THIS PAGE BLANK (USPTO)

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1365R2C1Serial No.
10/649,762LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)Applicant
Daniel J. Burdick et al.Filing Date
26 Aug 2003Group
NOT KNOWN

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,120,649	17.10.78	Schechter, I.			
	* 2	4,665,077	12.05.87	Stringfellow et al.			
	* 3	4,871,743		Taylor et al.			03.10.89
	* 4	5,039,805		Alig et al.			13.08.91
	* 5	5,149,780	22.09.92	Plow et al.			
	* 6	5,288,854	22.02.94	Diamond et al.			
	* 7	5,340,800	23.08.94	Liu et al.			
	* 8	5,403,843	04.04.95	Akimoto et al.			
	* 9	5,424,399	13.06.95	Arnaout			
	*10	5,470,953	28.11.95	Gallatin et al.			
	*11	5,472,973	05.12.95	Perumattam			
	*12	5,695,760	09.12.97	Faanes et al.			
	*13	5,695,778	09.12.97	List			
	*14	5,739,141		Varney et al.			14.04.98

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	*15	JP 4193895	13.07.92	ABSTRACT ONLY				
	16	849256	24.06.98	EP				
	*17	EP 0325343	26.07.89	EP				
	*18	EP 0452660	23.10.91	EP				
	*19	325,343	26.07.89	EPO				
	*20	452,660	23.10.91	EPO				
	*21	530,537	10.03.93	EPO				
	*22	EP 314,863	02.11.87	EPO				
	*23	EP 362,526	11.04.90	EPO				
	*24	EP 362,531	11.04.90	EPO				
	*25	05-306226	19.11.93	JAPAN (ABSTRACT ONLY)				
	*26	WO 00/21920	20.04.00	PCT				
	*27	WO 90/03400	05.04.90	PCT				
	*28	WO 90/09989	07.09.90	PCT				
	*29	WO 90/10652	20.09.90	PCT				
	*30	WO 90/13316	15.11.90	PCT				
	*31	WO 91/19511	26.12.91	PCT				
	*32	WO 92/03473	05.03.92	PCT				
	*33	WO 94/11400	26.05.94	PCT				

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



THIS PAGE BLANK (USPTO)

U.S. Dept. of Commerce
Patent and Trademark Office

Serial No.
10/649,762

Applicant
Daniel J. Burdick et al.

Filing Date
26 Aug 2003

Group	NOT KNOWN
-------	-----------

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
*34		WO 94/13295	23.06.94	PCT				
*35		WO 95/28170	26.10.95	PCT				
*36		WO 97/08133	06.03.97	PCT				
*37		WO 99/10312	04.03.99	PCT				
*38		WO 99/11258	11.03.99	PCT				
*39		WO 99/26923	03.06.99	PCT				
*40		WO 99/35163	15.07.99	PCT				
*41		WO 99/36393	22.07.99	PCT				
*42		WO 99/49856	07.10.99	PCT				


OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



THIS PAGE BLANK (USPTO)



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

David Evans is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Genentech, Inc. to prepare and prosecute patent applications in which Genentech, Inc. is the assignee of record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) David Evans ceases to lawfully reside in the United States, (ii) David Evans's employment with Genentech, Inc. ceases or is terminated, or (iii) David Evans ceases to remain or reside in the United States on an H1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: May 1, 2004

Harry L. Moatz

Director of Enrollment and Discipline



THIS PAGE BLANK (USPTO)